Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes

NCT01399645 · Completed

Last updated 2026-05-28

This clinical trial compares the effects of the medication liraglutide versus insulin on liver fat in adults with type 2 diabetes and fatty liver disease.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 35 people

Who can join Ages 18+ · all sexes

Timeline Started 2011-05 · est. completion 2014-06

Where 1 site · Canada

What this study is testing ClinicalTrials.gov NCT01399645 ↗

Description as written by the study sponsor.

This study is conducted to test the hypothesis that in type 2 diabetic adults with fatty liver who are resistant to metformin, treatment with liraglutide in combination with metformin will cause an absolute reduction in liver fat superior to insulin-metformin treatment within a 3-month period, as measured by magnetic resonance imaging (MRI).

Treatments tested

Liraglutide-metformin vs insulin-metformin also known as Liraglutide, Victoza, Insulin glargine, Lantus Drug

Liraglutide (Victoza, Novo Nordisk) at a dose of 0.6 - 1.8 mg subcutaneous per day. Insulin glargine (Lantus, Sanofi-Aventis) with an initial bedtime starting dose of 10 IU.

Main thing measured	To determine liver fat fraction evolution induced by liraglutide and insulin
Sponsor	Centre hospitalier de l'Université de Montréal (CHUM)
Conditions studied	Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Type 2 Diabetes
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01399645 ↗